Alex A. Adjei
YOU?
Author Swipe
View article: Clone wars: Evidence of clonal stability in a longitudinal prospective cohort of cancer survivors with serial NGS analysis
Clone wars: Evidence of clonal stability in a longitudinal prospective cohort of cancer survivors with serial NGS analysis Open
Introduction: Hematopoietic stem and progenitor cells with preleukemic mutations (mutns), collectively termed clonal hematopoiesis (CHIP) serve as the cellular origin of myeloid neoplasms (MN). While risk of MN development varies, its natu…
View article: Is PPM1D a potential driver of myeloid malignancy transformation in neuroendocrine tumor (NET) patients: An underrecognized malignant CHIPeRpetRaTor?
Is PPM1D a potential driver of myeloid malignancy transformation in neuroendocrine tumor (NET) patients: An underrecognized malignant CHIPeRpetRaTor? Open
Background: Building on our prior work showing high baseline CHIP prevalence and cytopenias in NET patients (pts) receiving PRRT, we used NANETS support to analyze a new cohort with matched pre- (pre-tx) and post-treatment (post-tx) periph…
View article: CTNI-08. WSD0922-FU THERAPY IN PATIENTS WITH EGFR MUTANT GLIOBLASTOMA – UPDATES FROM THE DOSE EXPANSION COHORTS OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)
CTNI-08. WSD0922-FU THERAPY IN PATIENTS WITH EGFR MUTANT GLIOBLASTOMA – UPDATES FROM THE DOSE EXPANSION COHORTS OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914) Open
WSD0922-Fu is an oral, CNS-penetrant, small molecule EGFR inhibitor which potently inhibits EGFR aberrations specific to non-small cell lung cancer (NSCLC) and glioblastoma (GBM). MC1914 (NCT04197934) is a first-in-human phase 1 trial in p…
View article: Where Do We Go With the Combination of Immune Checkpoint Inhibitors With Anti-Angiogenesis in Advanced NSCLC?
Where Do We Go With the Combination of Immune Checkpoint Inhibitors With Anti-Angiogenesis in Advanced NSCLC? Open
View article: Artificial Intelligence, Ghost Writers, and Scientific Integrity
Artificial Intelligence, Ghost Writers, and Scientific Integrity Open
View article: Creating a health empowerment website with teens: information for the evolving teenager (iuveo.org)
Creating a health empowerment website with teens: information for the evolving teenager (iuveo.org) Open
View article: A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors Open
Intravenous KO-947 had a generally tolerable safety profile with minimal gastrointestinal toxicity compared with oral administration of other ERK inhibitors.
View article: A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors
A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors Open
NCT03237390.
View article: Long-Term Outcomes of Extensive-Stage Small Cell Lung Cancer Treated with Chemotherapy or Chemo-Immunotherapy: A Propensity Score Adjusted Cohort Study
Long-Term Outcomes of Extensive-Stage Small Cell Lung Cancer Treated with Chemotherapy or Chemo-Immunotherapy: A Propensity Score Adjusted Cohort Study Open
View article: The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Anti-Tumor Surveillance Activation
The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Anti-Tumor Surveillance Activation Open
View article: Care Models for Cancer Survivors
Care Models for Cancer Survivors Open
The population of cancer survivors is on the rise due to an increase in cancer incidence and a decline in cancer mortality. This growing survivor population creates a number of challenges. Although there have been improvements in care plan…
View article: Sex differences in the pharmacokinetics of anticancer drugs: a systematic review
Sex differences in the pharmacokinetics of anticancer drugs: a systematic review Open
Significant sex differences in PK have been identified including commonly used drugs of different classes, such as 5-fluorouracil, doxorubicin, paclitaxel, regorafenib, atezolizumab, and temozolomide. The risk-benefit ratio for such antica…
View article: Exploring Approaches in Green Technical and Vocational Education Training (TVET): A Systematic and Bibliometric Review
Exploring Approaches in Green Technical and Vocational Education Training (TVET): A Systematic and Bibliometric Review Open
This study identifies and analyzes the main research areas related to green technical and vocational education training (TVET). It focuses on evaluating the extent of its integration into TVET programs. The research explores the link betwe…
View article: Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma
Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma Open
Purpose: To investigate the molecular characteristics of and potential for precision medicine in KRAS wildtype pancreatic ductal adenocarcinoma (PDAC). Patients and Methods: We investigated 27 patients with KRASWT PDAC at our institution. …
View article: A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors
A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors Open
Background: Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine is synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose limiting toxicities …
View article: A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors Open
Background: Bimiralisib is a pan-PI3K/mTOR inhibitor demonstrating antitumor efficacy in preclinical models. The objectives of this study were to identify a maximum tolerated dose (MTD), pharmacokinetics (PK), a dosing schedule, and advers…
View article: Update in Precision Oncology in Non-small Cell Lung Cancer
Update in Precision Oncology in Non-small Cell Lung Cancer Open
Treatments for lung cancer have historically been considered “one-size-fits-all” The development of Precision Oncology, however, has led to increased recognition of non-small cell lung cancer (NSCLC) as a molecularly complex amalgam of dis…
View article: Editorial Board
Editorial Board Open
View article: A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms
A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms Open
This clinical case presents a patient with NSCLC who experienced on-target resistant mutations and tumor cell transformation from adenocarcinoma to large cell neuroendocrine and small cell carcinoma. Our patient was successfully treated wi…
View article: Editorial Board
Editorial Board Open
View article: A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia
A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia Open
Background Despite recent approval of several new agents, relapsed acute lymphoblastic leukemia (ALL) remains challenging to treat. Sapanisertib (MLN0128/TAK‐228) is an oral TORC1/2 inhibitor that exhibited preclinical activity against ALL…
View article: CTNI-03. EFFICACY OF WSD0922-FU IN OSIMERTINIB-RESISTANT NSCLC WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES – UPDATES FROM THE DOSE ESCALATION COHORT OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914)
CTNI-03. EFFICACY OF WSD0922-FU IN OSIMERTINIB-RESISTANT NSCLC WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES – UPDATES FROM THE DOSE ESCALATION COHORT OF A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL (MC1914) Open
WSD0922-Fu is an oral, CNS-penetrant, small molecule EGFR inhibitor which potently inhibits EGFR aberrations specific to non-small cell lung cancer (NSCLC) and high-grade astrocytoma (HGA). MC1914 (NCT04197934) is a first-in-human phase 1 …
View article: Editorial Board
Editorial Board Open
View article: 729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors
729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors Open
Background GI-102 (CD80-IL2v3) is a novel immunocytokine, designed to direct IL-2v to tumor and immune cells. IL-2v3 of GI-102 is designed to abolish the affinity to IL-2Rα thereby maximizing expansion of cytotoxic T and NK cells but not T…
View article: Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study Open
View article: 713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation Open
View article: The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024
The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024 Open
View article: Editorial Board
Editorial Board Open
View article: Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial Open
View article: TIPS-09 FIRST-IN-HUMAN PHASE 1 TRIAL OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF WSD0922-FU (NCT04197934): TRIAL IN PROGRESS
TIPS-09 FIRST-IN-HUMAN PHASE 1 TRIAL OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF WSD0922-FU (NCT04197934): TRIAL IN PROGRESS Open
WSD0922-Fu is an oral, central nervous system (CNS)-penetrant, small molecule, ATP non-competitive, reversible EGFR inhibitor which potently inhibits EGFR aberrations specific to non-small cell lung cancer (NSCLC) and high-grade astrocytom…